None (Healthy Adults)
Conditions
Interventions
Intakes of test tablets for 8 weeks
Intakes of placebo tablets for 8 weeks
Sponsors
Kirin Holdings Company, Limited
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Men and women who are between 30 and 59 years old at the time of obtaining consent 2) Subjects who are judged to be in good health and to be without any chronic physical diseases by the chief physician 3) Subjects who are concerned about decrease of moisture and elasticity with skin aging 4) Subjects who are defined skin type II or III (Japan Cosmetic Industry Association SPF Measurement Standard revised in 2007, self-report) 5) Subjects who are able to be measured UV erythema on the back skin 6) Subjects whose MED is the second, third, fourth or fifth highest irradiation energy dose 7) Subjects who are able to come to the test site on all visit dates 8) Subjects who are able to read and understand the informed consent form and able to give voluntary consent in the study 9) Subjects who are deemed appropriate to participate in the study by the chief physician.
Exclusion criteria
Exclusion criteria: Subjects 1 who are currently, or have been within the past 4 weeks, undergoing drug treatment for any disease, or who regularly use pharmaceutical or quiasi-drug products for purposes without disease treatment 2 who have been diagnosed with photosensitivity 3 who take drugs that affect the photosensitivity 4 who have any factors that may affect the results of the measurement 5 who are scheduled to undergo or have undergone within the past 4 weeks any special skincare treatment 6 who continuously use skincare products, or health foods that emphasize efficacy related to the efficacy studied in this study 7 who have changed or newly started using basic cosmetics or sunscreen products within the past 4 weeks 8 who are unable to quit the intake of supplements or health foods 9 who cannot control their intake of yogurt and intestinal preparations 10 who have been within the past 4 weeks or will be exposed to much UV radiation than they are exposed to in their daily lives 11 who are at risk of developing allergies to foods 12 who continuously use drugs for freckles, pigmentation and melasma 13 who work night shifts or day/night shifts 14 who are likely to change their lifestyle 15 who are undergoing treatment for the treatment or prevention, or who are judged to require treatment 16 who continuously use or take anti-inflammatory drugs more than once a month 17 who have a history of serious diseases (glucose metabolism, lipid metabolism, etc.) 18 who are undergoing climacteric symptom or postmenopausal hormone replacement therapy, or those who have been undergoing such therapy for at least 6 months 19 who refuse to disclose their biological sex 20 with a history of alcohol or drug dependence 21 with a smoking habit 22 who are pregnant or lactating, or those who are likely to become pregnant 23 who participate in with in the past 4 weeks or plan to participate in any other human study 24 who are jedged unsuitable as subjects by the chief physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Skin color (a*) on UV-irradiated site | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluation of skin condition Blood biochemical analysis | — |
Countries
Japan
Contacts
Public ContactYuma Yoshida
DRC Co., Ltd. Product testing Department
Outcome results
None listed